Sandoz Italia

Name

Sandoz Italia

Website

https://sandoz.it

Company type

Private

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

akta.pro secondary industry

Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

Keywords

• Generic pharmaceuticals
• Biosimilars medicines
• Prescription medicines
• Pharmaceutical manufacturing
• Italian healthcare market

GTM type

B2B

Offering type

Hardware or Manufacturing

Core offering

The source data contains only the page title 'Sandoz Italia' and the URL https://www.sandoz.com/it-it/. No description of specific products, services, or core offering is provided in the input. The entity appears as the Italian-localized web presence of the global Sandoz pharmaceutical brand.

Differentiator

Problem solved

Functional benefit

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves2 records

Expansion highlights2 records

Broad incumbents

• Novartis: Former parent of the Sandoz Group (divested in 2023) and a major innovative medicines incumbent operating Novartis Italia; comparable as a broad Swiss-anchored pharma incumbent with a substantial Italian affiliate, although its portfolio is now focused on branded innovative drugs rather than generics.

Direct peers

• DOC Generici: Italy-domiciled generic pharmaceutical manufacturer focused on off-patent prescription medicines sold through Italian retail pharmacies and wholesalers; directly comparable to Sandoz Italia as a home-market generic competitor with overlapping therapeutic coverage and channel mix.
• Zentiva: European-focused generic medicines company (Czech roots, now owned by Sanofi-adjacent investor group) selling through Italian retail and hospital channels; directly comparable as a regional generic competitor to Sandoz Italia.
• Viatris: Global generics and complex generics player (formed from Mylan and the Upjohn division of Pfizer) with an established Italian commercial organization (Viatris Italia) that competes with Sandoz Italia across off-patent prescription generics, biosimilars, and branded specialty generics in Italy.
• Krka: Slovenian generic pharmaceutical producer with strong Central/Southern European distribution, including Italy; competes with Sandoz Italia in generic prescription generics sold through retail pharmacy and public tender channels.
• Stada Arzneimittel: European-headquartered generics, specialty and consumer healthcare group with an Italian affiliate (STADA Italia) selling generic prescription medicines through the same pharmacy and hospital channels that Sandoz Italia serves, making it a directly comparable European-focused peer.
• Aurobindo Pharma: Indian-headquartered global generic manufacturer with a material European and Italian commercial footprint (Aurobindo Italia) competing in the same generic prescription and tender markets as Sandoz Italia, with comparable API-to-finished-dose integration.
• Teva Pharmaceutical Industries: World's largest generic medicines manufacturer with a direct Italian subsidiary (Teva Italia) competing head-to-head with Sandoz Italia across generic small molecules and a growing biosimilars portfolio in the same Italian retail, hospital, and tender channels.

Emerging players

• Alvotech: Iceland-headquartered biosimilars pure-play with growing European commercial partnerships; overlaps with Sandoz Italia's biosimilars ambitions in Italy, though narrower in scope (biosimilars only) and earlier in commercial maturity.

Regional players

• Angelini Pharma: Italy-headquartered pharmaceutical group with branded specialty, consumer health and select generic exposure; regionally comparable to Sandoz Italia as a large Italian pharma player, though its portfolio is more weighted to branded/OTC than pure generics.

Market position

Competitive moat4 records

Key highlights2 records

Customer concentration

• LinkedInlinkedin.com/company/sandoz-italia

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sandoz Italia